Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more
Market Cap & Net Worth: Qingdao Baheal Medical INC. (301015)
Qingdao Baheal Medical INC. (SHE:301015) has a market capitalization of $1.60 Billion (CN¥11.77 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #10664 globally and #2408 in its home market, demonstrating a 1.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qingdao Baheal Medical INC.'s stock price CN¥22.40 by its total outstanding shares 525624077 (525.62 Million).
Qingdao Baheal Medical INC. Market Cap History: 2021 to 2026
Qingdao Baheal Medical INC.'s market capitalization history from 2021 to 2026. Data shows change from $2.00 Billion to $1.60 Billion (-16.25% CAGR).
Qingdao Baheal Medical INC. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qingdao Baheal Medical INC.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Qingdao Baheal Medical INC.'s market cap is 0.21 times its annual revenue
0.32x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.51x
Qingdao Baheal Medical INC.'s market cap is 2.51 times its annual earnings
10.44x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.00 Billion | $7.05 Billion | $421.64 Million | 0.28x | 4.74x |
| 2022 | $1.62 Billion | $7.51 Billion | $506.60 Million | 0.22x | 3.20x |
| 2023 | $2.51 Billion | $8.26 Billion | $712.06 Million | 0.30x | 3.52x |
| 2024 | $1.73 Billion | $8.09 Billion | $691.59 Million | 0.21x | 2.51x |
Competitor Companies of 301015 by Market Capitalization
Companies near Qingdao Baheal Medical INC. in the global market cap rankings as of March 18, 2026.
Key companies related to Qingdao Baheal Medical INC. by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #164 globally with a market cap of $115.38 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #340 globally with a market cap of $64.39 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #428 globally with a market cap of $51.10 Billion USD.
- Sigma Healthcare Limited (OTCGREY:SIGGF): Ranked #1455 globally with a market cap of $12.16 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #164 | McKesson Corporation | NYSE:MCK | $115.38 Billion | $943.25 |
| #340 | Cencora Inc. | NYSE:COR | $64.39 Billion | $345.88 |
| #428 | Cardinal Health Inc | NYSE:CAH | $51.10 Billion | $217.59 |
| #1455 | Sigma Healthcare Limited | OTCGREY:SIGGF | $12.16 Billion | $1.88 |
Qingdao Baheal Medical INC. Historical Marketcap From 2021 to 2026
Between 2021 and today, Qingdao Baheal Medical INC.'s market cap moved from $2.00 Billion to $ 1.60 Billion, with a yearly change of -16.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.60 Billion | -5.08% |
| 2025 | CN¥1.69 Billion | -2.52% |
| 2024 | CN¥1.73 Billion | -30.79% |
| 2023 | CN¥2.51 Billion | +54.55% |
| 2022 | CN¥1.62 Billion | -18.80% |
| 2021 | CN¥2.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Qingdao Baheal Medical INC. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.60 Billion USD |
| MoneyControl | $1.60 Billion USD |
| MarketWatch | $1.60 Billion USD |
| marketcap.company | $1.60 Billion USD |
| Reuters | $1.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.